Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Haemonetics Corporation (HAE)

NYSE: HAE · Surgical & Medical Instruments & Apparatus · Boston, MA

Our rating: Cautious

Call changed from Neutral to Cautious at $119.93, moderate conviction, November 6, 2026.

Breaks if: The Cautious call is wrong if Haemonetics reports organic revenue growth above 2% in each of the next two quarterly filings — at that point the top-line deterioration thesis dissolves and the FCF multiple earns a growth premium. Conversely, if the stock falls more than 20% over the next year to roughly $96 or below, the FCF yield re-rates toward 6% and the valuation objection softens considerably, warranting a reassessment toward Neutral.

Key figures

Market value$5.5B
Revenue, last 12 months$1.4B
Net income, last 12 months$104M
Free cash flow, last 12 months$298M
Price to earnings52.7×
Free cash flow yield5.5%
Dividend yield0.0%
Operating margin12.8%
Return on equity11.9%
Beta to the S&P 5000.50
Volatility, annualized45.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 26, 2026$358M9.3%$1.00$113M
June 27, 2026$339M5.6%$0.72$44M
March 28, 2026$346M4.8%$-0.41$53M
December 27, 2025$339M−2.7%$0.95$87M
September 27, 2025$327M−5.3%$0.81$106M
June 28, 2025$321M−4.4%$0.70$14M
March 29, 2025$331M−3.7%$1.17$101M
December 28, 2024$349M3.7%$0.74$35M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

16 ledger entries and 71 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.